Foghorn Therapeutics Inc. (FHTX)
| Market Cap | 124.12M -52.7% |
| Revenue (ttm) | 36.74M +52.0% |
| Net Income | -64.58M |
| EPS | -0.97 |
| Shares Out | 59.39M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 917,105 |
| Open | 1.920 |
| Previous Close | 1.970 |
| Day's Range | 1.906 - 2.150 |
| 52-Week Range | 1.790 - 7.610 |
| Beta | 3.01 |
| Analysts | Buy |
| Price Target | 6.00 (+187.08%) |
| Est. Earnings | Nov 4, 2026 |
About FHTX
Foghorn Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of medicines targeting genetically determined dependencies within the chromatin regulatory system in the United States. The company uses its proprietary Gene Traffic Control platform to identify, validate, and potentially drug targets within the system. It is developing therapies for mutant; non-small cell lung; endometrial, cervical, ovarian, and bladder cancer; and diffuse large B-cell lymphoma, as well as various acute myeloid leuk... [Read more]
Financial Performance
In 2025, Foghorn Therapeutics's revenue was $30.91 million, an increase of 36.75% compared to the previous year's $22.60 million. Losses were -$74.28 million, -14.24% less than in 2024.
Financial StatementsAnalyst Summary
According to 10 analysts, the average rating for FHTX stock is "Buy." The 12-month stock price target is $6.0, which is an increase of 187.08% from the latest price.
News
Wedbush downgrades Foghorn on end of Lilly collaboration
Wedbush downgraded Foghorn Therapeutics (FHTX) to Neutral from Outperform with a price target of $2, down from $10, after the company and Eli Lilly (LLY) elected not to advance FHD-909…
Foghorn Therapeutics downgraded to Neutral from Outperform at Wedbush
Wedbush analyst Robert Driscoll downgraded Foghorn Therapeutics (FHTX) to Neutral from Outperform with a price target of $2, down from $10.
Foghorn Therapeutics price target lowered to $5 from $12 at Guggenheim
Guggenheim lowered the firm’s price target on Foghorn Therapeutics (FHTX) to $5 from $12 and keeps a Buy rating on the shares after the company announced that they and partner…
Foghorn Therapeutics price target lowered to $5 from $13 at H.C. Wainwright
H.C. Wainwright lowered the firm’s price target on Foghorn Therapeutics (FHTX) to $5 from $13 and keeps a Buy rating on the shares after the company announced the discontinuation of…
Foghorn Therapeutics downgraded to Hold from Buy at TD Cowen
TD Cowen downgraded Foghorn Therapeutics (FHTX) to Hold from Buy without a price target The company and Eli Lilly’s decision not to advance FHD-909 into dose expansion, which in turn…
Foghorn Therapeutics downgraded to Neutral from Buy at BTIG
BTIG downgraded Foghorn Therapeutics (FHTX) to Neutral from Buy after the company announced partner Eli Lilly (LLY) will not advance the FHD-909 program or the SMARCA2 degrader into clinical expansion...
Foghorn Therapeutics downgraded at Citizens after FHD-909 discontinuation
As previously reported, Citizens analyst Silvan Tuerkcan downgraded Foghorn Therapeutics (FHTX) to Market Perform from Outperform after the company and partner Eli Lilly (LLY) announced the discontinu...
Foghorn Therapeutics downgraded to Market Perform from Outperform at Citizens
Citizens downgraded Foghorn Therapeutics (FHTX) to Market Perform from Outperform.
Foghorn Therapeutics price target lowered to $5 from $12 at Stifel
Stifel analyst Laura Prendergast lowered the firm’s price target on Foghorn Therapeutics (FHTX) to $5 from $12 and keeps a Buy rating on the shares. The firm notes the company…
Eli Lilly (LLY) Ends Cancer Development Deal with Foghorn Therapeutics
Foghorn plans to layoff 40% of its staff.
Foghorn Therapeutics drops 44% after scrapping FHD-909 program
Sahres of Foghorn Therapeutics (FHTX) have fallen about 44% to $2.00 in pre-market trading after the company announced that, following a review of clinical data from the Phase 1 dose…
Foghorn to cut 40% of workforce after scrapping Lilly-partnered cancer drug
Foghorn Therapeutics said on Thursday it has discontinued development of an experimental cancer drug partnered with Eli Lilly after it failed to show enough benefit in an early-stage trial.
Foghorn to Slash 40% of Jobs as Lilly Cancer Partnership Falls Apart
Foghorn Therapeutics and Eli Lilly don't plan any future collaborations following the dissolution of a cancer-drug partnership.
Foghorn, Lilly to not advance FHD-909 program, Foghorn to reduce workforce
Foghorn Therapeutics (FHTX) announced that, following a review of clinical data from the Phase 1 dose escalation trial of FHD-909, Foghorn and Lilly (LLY) have decided not to advance the…
Foghorn Therapeutics Provides Update on FHD-909 and Strategic Priorities
Foghorn and Lilly will not advance FHD-909; The Collaboration also will not advance the Selective SMARCA2 degrader program Company to focus resources on wholly owned pipeline, including a Selective EP...
Foghorn Therapeutics reports Q2 EPS (10c), consensus (23c)
Reports Q2 revenue $16.07M, consensus $7.93M. “Our FHD-909 trial in collaboration with Lilly continues to advance through dose escalation, with an initial focus on SMARCA4-mutant NSCLC, a setting wher...
Foghorn Therapeutics Provides Second Quarter 2026 Financial and Corporate Update
- FHD-909 (LY4050784) Phase 1 dose-escalation trial advancing as planned with non-small cell lung cancer (NSCLC) as the primary target population - Selective EP300 degraders with potential to treat mu...
Foghorn Therapeutics Quarterly report: Q2 2026
Foghorn Therapeutics has published its Q2 2026 quarterly earnings report on August 6, 2026.
Foghorn Therapeutics Earnings release: Q2 2026
Foghorn Therapeutics released its Q2 2026 earnings on August 6, 2026, summarizing the period's financial results.
Foghorn Therapeutics Slides: Investor presentation
Foghorn Therapeutics has posted slides in relation to its latest quarterly earnings report, which was published on August 6, 2026.
Step Pharma announces the appointment of Neil Gallagher as Non-Executive Director
Saint-Genis-Pouilly, France, 1 July 2026 – Step Pharma (“the Company”), the global leader in CTPS1 inhibition for targeted cancer treatment, today announces the appointment of Neil J. Gallagher, MD, P...
Foghorn Therapeutics Transcript: Goldman Sachs 47th Annual Global Healthcare Conference 2026
FHD-909, a selective SMARCA2 inhibitor for NSCLC, is nearing a key expansion decision with Eli Lilly in summer 2026, supported by a robust proprietary pipeline targeting oncology and autoimmune indications. Cash runway extends into H1 2028, with further funding needed for broader clinical development.
Foghorn Therapeutics to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference 2026
WATERTOWN, Mass., June 05, 2026 (GLOBE NEWSWIRE) -- Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases by...
Foghorn Therapeutics to Participate in Three Upcoming Investor Conferences in May
WATERTOWN, Mass., May 12, 2026 (GLOBE NEWSWIRE) -- Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases by ...
Foghorn Therapeutics reports Q1 EPS (29c), consensus (31c)
Reports Q1 revenue $3.27M, consensus $7.94M. “Our lead program, FHD-909, continues to advance through dose escalation in collaboration with Lilly. The trial is enriching for NSCLC patients with SMARCA...